Randomized controlled clinical trial evaluating the efficacy of hyperbaric oxygen therapy in facilitating the healing of chronic foot ulcers in diabetic patients: the study protocol

Jocefabia Reika Alves Lopes (reika.lopes@bol.com.br)
Faculdade de Medicina do ABC
Mariza D’Agostino Dias
Universidade de Sao Paulo
João Antonio Correa
Faculdade de Medicina do ABC
Maria Alice Bragagnolo Batalha
Hospital do Servidor Publico Estadual de Sao Paulo
Luanda Karla Dantas Guerra
Hospital Municipal de Imperatriz

Study protocol

Keywords: Diabetes Mellitus, Diabetic Foot, Hyperbaric Oxygenation, Wound Healing, Randomised controlled trials

DOI: https://doi.org/10.21203/rs.2.16819/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Diabetic limb ulcers are highly prevalent and contribute to a significant increase in cost for the treatment of these patients in health services. However, healing of these wounds is a major health problem and may even lead to amputation. The primary aim of the current study is to evaluate the efficacy of hyperbaric oxygen therapy (HBOT) in facilitating the healing of diabetic foot ulcers, in addition to secondarily evaluating whether it reduces the number of amputations and improves the quality of life in these patients.

Methods: A non-blind randomised clinical study will be conducted in the city of Imperatriz, Maranhão state, Brazil from 2019 to 2020, in diabetic patients with chronic foot ulcers (classified as Wagner grade 2, 3, and 4, persisting for more than one month). The outpatient follow-up for diabetic foot patients will be done at the Unified Health System, with a sample size of 120 patients (the randomisation allocation will be 1:1, being 60 patients for each arm). Half of the patients will receive standard treatment, i.e. dressings, debridement, antibiotics, and load relief, along with HBOT (HBOT group), and the other half will receive only standard treatment (control group). The patients of the HBOT group will be evaluated upon admission, after 10, 20, 30 and 35 HBOT sessions, and after six months and one year. The patients of the control group will also be evaluated at equivalent periods (upon admission, after 2, 4, 6 and 7 weeks, six months and one year). The SF-36 quality of life questionnaire will be filled upon admission and after three months of follow-up in both groups. The primary and secondary endpoints will be assessed with 1 year of follow-up.

Discussion: Diabetic foot ulcers are a highly prevalent complication of diabetes with serious consequences. A study to assess the efficacy of HBOT in healing the ulcers and reducing the rate of amputations in diabetic patients is justified, which will eventually aid in the development of guidelines for treating these ulcers.

Background

Globally, more than 400 million adults suffer from diabetes, and the treatment of diabetic foot ulcers is considered as an important public health issue [1]. According to the Ministry of Health of Brazil, the number of diabetic patients in Brazil increased by 61.8% between 2006 and 2016, and the prevalence increased from 5.5% to 8.9%, with more prevalence in women (9.9%) than in men (7.8%). Approximately one in every twenty diabetic patients develops foot ulcers in the first year, and approximately 10% of the patients with ulcers evolve to amputation in this period [2, 3].

Unhealed and infected wounds in diabetic foot cause damage in both tissues and bones, which leads to amputations in 85% of these individuals, and approximately 60% mortality has been reported after amputation during five years of follow-up [4-6].

Chronic changes that occur in the feet of diabetic patients, such as peripheral arterial disease, neuropathy with loss of protective sensitivity, deformities, and decreased mobility of the feet, are the main
challenges in the prevention and treatment of diabetic foot ulcers [7,8]. The treatment of diabetes and diabetic foot ulcers requires multiple approaches, which involve optimisation of glycaemic control, wound care, treatment of infections, load relief and revascularisation in ischemic cases [2, 9]. Unfortunately, even with optimal care, the rate of complete healing of the wounds stays approximately 60% per year [2, 10]. Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant therapy for patients with refractory ulcers [11, 12].

Normal wound healing occurs through the ordered and overlapping stages of haemostasis, inflammation, proliferation, and tissue remodelling, involving complex molecular and cellular interactions within the wound microenvironment [13]. Regardless of the aetiology of the wound, an adequate condition of the vasculature, including both macrocirculation and microcirculation, is critical for healing. Insufficient perfusion impairs angiogenesis, collagen deposition, and epithelialisation and may lead to sustained inflammation [14].

Among the advanced therapeutic interventions for wounds, HBOT has the unique ability to improve tissue hypoxia, reduce pathological inflammation, and mitigate ischemia-reperfusion injury [15].

Evidence on the effectiveness of HBOT in healing diabetic foot ulcers is variable. Some researchers have reported greater effectiveness when HBOT is compared to sham treatment or placebo [2, 16-19], but others found no differences [7, 20]. HBOT has also been reported to promote the resolution of infection and reduce the likelihood of amputation by some authors [17], but others have shown no benefit [7, 21].

A systematic review of randomized clinical trial data recently published by the Cochrane Collaboration [22] reported a significant improvement in short-term (6 weeks) wound healing, but no statistically significant difference was found in wound healing rates for long-term amputation and major or minor amputation favouring HBOT, thus, suggesting the need for further randomized studies to clarify these doubts.

Objectives

**Primary objective**

To assess whether HBOT along with the standard treatment of chronic diabetic foot ulcers is more effective in wound healing than the standard treatment alone.

**Secondary objective**

To assess whether HBOT, along with the standard treatment of chronic diabetic foot ulcers, reduces the number of major (transtibial and transfemoral) and minor amputations (toes and forefoot), and improves the quality of life of these patients, as compared to the standard treatment alone.
Hypothesis

Adding adjunctive treatment of HBOT to the standard treatment of diabetic foot ulcers, i.e. dressings, debridement, antibiotics, and load relief, can improve wound healing and reduce major amputations, improving the quality of life of these patients.

Methodology

Study Design

This is a parallel, two-arm, non-blinded, randomized controlled trial in the single center.

Study site

The study will be conducted in the city of Imperatriz, Maranhão in diabetic patients with chronic foot ulcers (classified as grade 2, 3 and 4 of Wagner [23] and persisting for more than one month). The outpatient follow-up for diabetic foot patients will be done at the SUS (Unified Health System - a public health service for the entire Brazilian population), with HBOT sessions being held in the CicatrizAR Clinic.

Sample and Study Period

The sample will consist of diabetic patients with chronic foot ulcers treated with standard methods, i.e. dressings, debridement, antibiotics, and load relief (control group), and to the other group will be added HBOT (HBOT group). The study will be conducted from 2019 to 2020.

The sample size has been calculated based on the formula for comparing two independent groups according to qualitative variables [24], with 95% confidence interval and 80% power. A wound healing rate of 90% was considered for the case group and the control group had less than 20% wound healing rate. Thus, the sample size comprised of 60 patients per group.

Trial Status

Registration number  RBR-7bd3xy. Registered 17 July 2019. The first recruitment was held on 04 July 2019 and the last recruitment is foreseen on 31 August 2020.

Eligibility criteria

The inclusion criteria of the study are adult patients (age > 18 years), stable clinical presentation, diabetes type 1 and 2, Wagner Grade 2, 3, and 4 foot ulcers, ulcers persisting for more than one month without cure, authorisation for the study, and patients of the SUS (Unified Health System).

Exclusion criteria of the study are failure to meet one of the inclusion criteria, patients with macroangiopathy (absent distal pulses), and patients with contraindications for HBOT, absolute or relative, patients on bleomycin chemotherapy, with chronic obstructive pulmonary disease, previous
spontaneous pneumothorax, chronic sinusitis, chronic otitis media, unstable angina, severe congestive heart failure, claustrophobia, severe dementia, depression, and history of seizures.

**Data collection**

The data collection will be performed in the diabetic foot outpatient clinic of the SUS and in the Cicatrizar clinic, using a standardised questionnaire provided in the Supporting Information, as well as with photographic recording of the ulcers, according to the timeline described in Figure 1.

Figure 1. The schedule of enrolment, interventions, and assessments.

**Randomization**

This is a parallel, two-arm, non-blinded, randomized controlled trial in which an randomization will be performed using a simple draw 1:1 by the research coordinator.

**Interventions**

The patients of the HBOT group will be evaluated upon admission, after 10, 20, 30 and 35 HBOT sessions and after six months and one year; and the control group will also be assessed at equivalent periods (upon admission, after 2, 4, 6 and 7 weeks, six months and one year) to clinically evaluate the ulcers and perform specific measures using the software ImageJ, developed at the National Institutes of Health (NIH, Bethesda, Maryland). The progression of the wounds and specific treatment such as appropriate bandage, antibiotic therapy, or need for some surgical intervention will be evaluated on a weekly basis. The HBOT sessions will be conducted five days a week, being carried out with patients in a multiplace chamber at 2.5 atmospheres absolute (ATA) and 100% O₃, with 10 minutes for compression and decompression, effective sessions of 90 minutes, with intervals of 5 minutes for each 30 minutes of treatment. The dressings will be done in both groups with Exufiber foam Ag® (Molnlycke, Gotemburgo, Suécia) or Mepilex® (Molnlycke, Gotemburgo, Suécia), which will be chosen according to the characteristics of wounds, with silver dressings for the infected injuries and a foam with polyurethane protective layer for wounds in which granulation tissue has formed. The progression of the wounds and specific treatment, such as appropriate bandage, antibiotic therapy, or need of some surgical intervention will be evaluated on a weekly basis.

The SF-36 quality of life questionnaire will be filled upon admission and after three months of follow-up in both the groups. On admission, the patients of both groups will undergo arterial Doppler ultrasound, and patients with macroangiopathy will be excluded from the research. Laboratory examinations, such as a haemogram, erythrocyte sedimentation rate, levels of C-reactive protein, creatinine, fasting blood glucose, and glycosylated haemoglobin will also be estimated only on admission.

**Primary outcome**
Wound healing will be assessed by evaluating the diameter of the lesions by specific software and periods, as described in the interventions.

**Secondary outcome**

Amputation rates will be assessed, with an evaluation of statistical significance between the groups. The evaluation of the domains of the SF-36 quality of life questionnaire will also be done in both groups. The data from this questionnaire upon admission and after three months of follow-up will be compared.

**Data analysis**

The collected data will be stored in a Microsoft Excel 2016 spreadsheet format. After checking for errors and inconsistencies, descriptive examinations will be performed by means of absolute and relative frequencies and measures of central tendency and variability. We will only analyze the data of patients who follow the intervention, those who do not continue the intervention will be considered sample loss. Blinding will be done for the researcher who will evaluate the final data and for the statistician.

The chi-square test or an equivalent test will be used to assess associations between the categorical variables, odds ratios (ORs), and confidence intervals will be calculated by means of logistic regression. Student's t-test or a similar non-parametric method will be used for the analysis of continuous variables. All examinations will be performed at 5% significance in the IBM SPSS® program, Version 24.0, 2016 (IBM, Armonk, New York, USA).

**Ethical aspects**

This study will be based on the principles of Resolution 466/12 of the National Health Council that regulates the research involving human subjects. The patients involved shall be duly informed and clarified about the importance and purpose of the study; if patients accept to participate, they will sign an informed consent form (see supporting information). The non-participation in the study or waiver, privacy, reliability, and anonymity of the participants will be guaranteed.

The study was initiated after approval by the Research Ethics Committee of the ABC University. It is registered with the Brazilian Registry of Clinical Trials (ReBEC) under the number RBR-7bd3xy.

**Adverse events**

This study is being conducted in accordance with the guidelines of the Brazilian Society of Hyperbaric Medicine (SBMH) and Undersea & Hyperbaric Medical Society (UHMS), and if adverse events occur (such as dizziness, seizure, pneumothorax, pneumomediastinum, nauseas, middle ear barotrauma, seizure, ear pain, confinement anxiety, hypoglycemic event and shortness of breath), these will be conducted according to these guidelines, as well as be documented and published later.
Discussion

The current study has been designed to compare the existing standard treatment for chronic foot ulcers of diabetic patients, i.e. dressings, debridement, antibiotics, load relief, and their combination with HBOT. Since we do not believe in comparing the two groups with pseudotherapy, it will not be performed on any patient as described by O'Reill et al. and Londahl et al.[7, 25]. Subpressurising or pressurising as a placebo would alter the normal physiology of patients' blood gases, which does not occur in standard treatment. Therefore, we believe in the power of evidence that can be provided with this proposed study model.

Abbreviations

HBOT, hyperbaric oxygen therapy
OR, odds ratio
SUS, Unified Health System

Declarations

Ethics approval and consent to participate

This research has been approved by the Research Ethics Committee of the Faculty of Medicine of ABC-SP, under opinion number 3.345.550, provided in the supporting files. Being registered in the Brazilian Registry of Clinical Trials (ReBEC) under the number RBR-7bd3xy, with the protocol: Does hyperbaric oxygen therapy facilitate healing of chronic foot ulcers in diabetics? It is in accordance with the Helsinki Declaration, with all participants signing the free and informed consent form, moment in which all the details of the project will be explained, from dressing changes, interventions, possible adverse effects of treatments, mainly from HBOT. The research coordinator will collect the informed consent form.

Consent for publication

Yes, patients authorize publication of research data upon signing the consent form.

Availability of data and materials

Data and materials will be available as soon as they are collected. The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

We, as the authors, declare no conflicts of interest in relation to the study.

Funding
Financial information: There was no funding by any institution.

Authors' contributions

JRAL, MD’AD, and JAC conceptualized the study. JRAL, MD’AD, and JAC designed the methodology. JRAL, MD’AD, JAC, MABB, and LKDG wrote the manuscript. JRAL, MD’AD, JAC, MABB, and LKDG reviewed and edited the manuscript. All authors adhere to the authorship guidelines of Trial and authors have agreed to publication.

Acknowledgments

We thank the hyperbaric doctors of the CicatrizAR clinic, who will assist in the execution of this study.

Protocol modifications

There will be no special criteria for discontinuing or modifying allocated interventions If it is necessary to make any major modifications to the research protocol, this change will be made available on Plataforma Brasil and ReBEC.

References

1. Humphrey LL, Kansagara D, Qaseem A, High Value Care Committee of the American College of P. World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee. Ann Intern Med. 2018;169(6):398-400.
2. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg. 2014;47(6):647-55.
3. Hunt DL. Diabetes: foot ulcers and amputations. BMJ Clin Evid. 2011;2011:0602.
4. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679-85.
5. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-28.
6. Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP, et al. Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care. 2006;29(10):2252-6.
7. Fedorko L, Bowen JM, Jones W, Oreopoulos G, Goeree R, Hopkins RB, et al. Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing
Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care. 2016;39(3):392-9.

8. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med. 2017;376(24):2367-75.

9. Alavi A, Sibbald RG, Mayer D, Goodman L, Botros M, Armstrong DG, et al. Diabetic foot ulcers: Part II. Management. J Am Acad Dermatol. 2014;70(1):21.e1-24.

10. Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Lammer J, et al. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev. 2012;28 (Suppl 1):179-217.

11. Lam G, Fontaine R, Ross FL, Chiu ES. Hyperbaric Oxygen Therapy: Exploring the Clinical Evidence. Adv Skin Wound Care. 2017;30(4):181-90.

12. Goldstein LJ. Hyperbaric oxygen for chronic wounds. Dermatol Ther. 2013;26(3):207-14.

13. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89(3):219-29.

14. Castilla DM, Liu ZJ, Velazquez OC. Oxygen: Implications for Wound Healing. Adv Wound Care (New Rochelle). 2012;1(6):225-30.

15. Fife CE, Eckert KA, Carter MJ. An Update on the Appropriate Role for Hyperbaric Oxygen: Indications and Evidence. Plast Reconstr Surg. 2016;138(3):107S-16S.

16. Londahl M, Landin-Olsson M, Katzman P. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabet Med. 2011;28(2):186-90.

17. Liu R, Li L, Yang M, Boden G, Yang G. Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers. Mayo Clin Proc. 2013;88(2):166-75.

18. Kessler L, Bilbault P, Ortega F, Grasso C, Passemand R, Stephan D, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26(8):2378-82.

19. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg. 2003;25(6):513-8.

20. Margolis DJ, Gupta J, Hoffstad O, Papdopoulos M, Glick HA, Thom SR, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care. 2013;36(7):1961-6.

21. O’Reilly D, Pasricha A, Campbell K, Burke N, Assasi N, Bowen JM, et al. Hyperbaric oxygen therapy for diabetic ulcers: systematic review and meta-analysis. Int J Technol Assess Health Care. 2013;29(3):269-81.

22. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2015(6):CD004123.
23. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981;2(2):64-122.

24. Miot HA. Tamanho da amostra em estudos clínicos e experimentais. J Vasc Bras. 2011;10(4):275-8.

25. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010;33(5):998-1003.

**Figures**

![Image of a table showing the schedule of enrolment, interventions, and assessments.]

**Figure 1**

The schedule of enrolment, interventions, and assessments.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [ResearchQuestionnaire.pdf](#)
